28 related articles for article (PubMed ID: 591617)
1. 3D, large-area NiCo
Durai L; Badhulika S
Mikrochim Acta; 2021 Oct; 188(11):371. PubMed ID: 34625854
[TBL] [Abstract][Full Text] [Related]
2. The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.
Tamae D; Mostaghel E; Montgomery B; Nelson PS; Balk SP; Kantoff PW; Taplin ME; Penning TM
Chem Biol Interact; 2015 Jun; 234():332-8. PubMed ID: 25514466
[TBL] [Abstract][Full Text] [Related]
3. Testosterone stimulates Duox1 activity through GPRC6A in skin keratinocytes.
Ko E; Choi H; Kim B; Kim M; Park KN; Bae IH; Sung YK; Lee TR; Shin DW; Bae YS
J Biol Chem; 2014 Oct; 289(42):28835-45. PubMed ID: 25164816
[TBL] [Abstract][Full Text] [Related]
4. Flutamide attenuates pro-inflammatory cytokine production and hepatic injury following trauma-hemorrhage via estrogen receptor-related pathway.
Shimizu T; Yu HP; Hsieh YC; Choudhry MA; Suzuki T; Bland KI; Chaudry IH
Ann Surg; 2007 Feb; 245(2):297-304. PubMed ID: 17245185
[TBL] [Abstract][Full Text] [Related]
5. Endocrine mechanisms of suppressive effect of low dose estrogen-antiandrogen treatment on androgen-dependent organs of male rats.
Reznikov AG; Varga SV; Chaikovskaya LV; Tarasenko LV; Polyakova LI
J Endocrinol Invest; 1996 Nov; 19(10):654-8. PubMed ID: 9007695
[TBL] [Abstract][Full Text] [Related]
6. Further evidence for the participation of 5 beta-steroids in the development of a porphyria induced by hexachlorobenzene.
Graef V; Golf SW; Tyrell C
Arch Toxicol; 1982 Sep; 50(3-4):233-9. PubMed ID: 7149988
[TBL] [Abstract][Full Text] [Related]
7. Androgens during different modes of endocrine treatment of prostatic cancer.
Pousette A; Carlström K; Stege R
Urol Res; 1989; 17(2):95-8. PubMed ID: 2734983
[TBL] [Abstract][Full Text] [Related]
8. Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.
Brogden RN; Clissold SP
Drugs; 1989 Aug; 38(2):185-203. PubMed ID: 2670515
[TBL] [Abstract][Full Text] [Related]
9. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma.
Delaere KP; Van Thillo EL
Semin Oncol; 1991 Oct; 18(5 Suppl 6):13-8. PubMed ID: 1948117
[TBL] [Abstract][Full Text] [Related]
10. New concepts in studying the control of normal and cancer growth of the prostate.
Coffey DS; Pienta KJ
Prog Clin Biol Res; 1987; 239():1-73. PubMed ID: 3309951
[No Abstract] [Full Text] [Related]
11. The effect of flutamide on testosterone metabolism and the plasma levels of androgens and gonadotropins.
Hellman L; Bradlow HL; Freed S; Levin J; Rosenfeld RS; Whitmore WF; Zumoff B
J Clin Endocrinol Metab; 1977 Dec; 45(6):1224-9. PubMed ID: 591617
[TBL] [Abstract][Full Text] [Related]
12. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
[TBL] [Abstract][Full Text] [Related]
13. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
14. Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue.
Ayub M; Levell MJ
Clin Endocrinol (Oxf); 1990 Mar; 32(3):329-39. PubMed ID: 2140542
[TBL] [Abstract][Full Text] [Related]
15. The effect of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer.
Balzano S; Cappa M; Migliari R; Scarpa RM; Danielli E; Campus G; Pintus C; Sica V; Usai E; Martino E
J Endocrinol Invest; 1988 Nov; 11(10):693-6. PubMed ID: 2852689
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
